Arcturus adds $50M Meiji investment as Q3 pipeline milestones stay on track
Meiji Seika Pharma bought a stake in Arcturus at a premium to fund OTC deficiency work and validate the LUNAR 2.0 platform, layered onto Q3 trial updates.
SEC filing (5)
5 stories
Meiji Seika Pharma bought a stake in Arcturus at a premium to fund OTC deficiency work and validate the LUNAR 2.0 platform, layered onto Q3 trial updates.
SEC filing (5)
Eikon Therapeutics disclosed updated lung cancer data, a registrational trial start, and an IND filing for a new prostate cancer drug, alongside $461.7 million in cash.
SEC filing (12)
Alector plans an October 13 webinar on its anti-Abeta, tau, and alpha-synuclein programs following its $100 million upfront Genentech license and updated cash guidance into 2029.
SEC filing (5)